Sort   by:  
 Page size 
UnknownEvaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.
Not available
S-EPMC7115814 | biostudies-literature
UnknownA kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML.
Not available
S-EPMC6834439 | biostudies-literature
UnknownMolecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
Not available
S-EPMC7012478 | biostudies-literature
UnknownIdentification of CD203c as a New Basophil-Specific Flow-Marker in Ph<sup>+</sup> Chronic Myeloid Leukemia.
Not available
S-EPMC9818308 | biostudies-literature
UnknownImmunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
Not available
S-EPMC6747233 | biostudies-literature
UnknownCell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
Not available
S-EPMC7581453 | biostudies-literature
UnknownThe pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.
Not available
S-EPMC5620205 | biostudies-literature
UnknownCCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
Not available
S-EPMC7115851 | biostudies-literature
UnknownTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
Not available
S-EPMC4896384 | biostudies-literature
UnknownCDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1<sup>T315I</sup>+ clones in TKI-resistant CML.
Not available
S-EPMC6921367 | biostudies-literature
Sort   by:  
 Page size